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ARTICLE
Proﬁling surface proteins on individual exosomes
using a proximity barcoding assay
Di Wu 1,2,3, Junhong Yan1, Xia Shen 4,5,6, Yu Sun 7,11, Måns Thulin 8,12, Yanling Cai9, Lotta Wik1,
Qiujin Shen1, Johan Oelrich 3, Xiaoyan Qian 2, K. Louise Dubois10, K. Göran Ronquist 10, Mats Nilsson2,
Ulf Landegren 1 & Masood Kamali-Moghaddam 1
Exosomes have been implicated in numerous biological processes, and they may serve as
important disease markers. Surface proteins on exosomes carry information about their
tissues of origin. Because of the heterogeneity of exosomes it is desirable to investigate them
individually, but this has so far remained impractical. Here, we demonstrate a proximity-
dependent barcoding assay to proﬁle surface proteins of individual exosomes using antibody-
DNA conjugates and next-generation sequencing. We ﬁrst validate the method using artiﬁcial
streptavidin-oligonucleotide complexes, followed by analysis of the variable composition of
surface proteins on individual exosomes, derived from human body ﬂuids or cell culture
media. Exosomes from different sources are characterized by the presence of speciﬁc
combinations of surface proteins and their abundance, allowing exosomes to be separately
quantiﬁed in mixed samples to serve as markers for tissue-speciﬁc engagement in disease.
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Exosomes are a subclass of membrane-coated extracellularvesicles with sizes of 30–100 nm, which are released fromcells by exocytosis. Exosomes are found in most body ﬂuids,
and they have been shown to play key roles in processes such as
coagulation, intercellular signaling, immune responses, and cel-
lular waste management1. Compelling evidence suggests that
exosomes may have a role in the spread of cancer from a primary
tumor to metastasis sites2,3, and they are promising as tissue-
speciﬁc biomarkers for liquid biopsy4,5. Exosomes are highly
heterogeneous in molecular composition6–9, and their surface
proteins bear characteristics of their tissues of origin10,11, ren-
dering speciﬁc subclasses of these vesicles promising to demon-
strate pathology affecting speciﬁc tissues12–14. Accordingly, it is
important to investigate exosomes individually as such informa-
tion may be lost in bulk-level analyses.
Recently, new technologies have emerged that improve oppor-
tunities for detection of exosomes. Imaging ﬂow cytometry over-
comes obstacles in traditional ﬂow cytometry by including a CCD
camera with a 60× objective, allowing detection of vesicles with sizes
below 500 nm through enhanced ﬂuorescence15. However, only a
small number of ﬂuorophore-labeled antibodies can be resolved in
this way. Nano-plasmonic sensors utilize sophisticated nanohole
arrays to ﬁrst isolate single exosomes via speciﬁc capture antibodies,
followed by protein proﬁling using detection antibodies16. The
combination of capture and detection antibodies limits the analysis
to two protein targets per exosome, and sandwich immune assays
are limited to analyzing pairs of proteins on exosomes in bulk.
Therefore, methods are needed to more comprehensively proﬁle
proteins in high multiplex for individual exosomes.
DNA-assisted immunoassays combine afﬁnity probes with con-
jugated ampliﬁable oligonucleotides, converting protein identities to
DNA sequences for protein detection even at the level of single
molecules or molecular complexes. In particular, proximity ligation
or extension assays can offer improved speciﬁcity of analysis and
confer information about protein compositions via ligation or
extension of pairs of DNA strands brought in proximity via their
conjugated antibodies17–19. A multiple-recognition proximity liga-
tion assay (4PLA) has been developed where exosomes are captured
by an immobilized antibody, whereupon four antibody-DNA
conjugates give rise to ampliﬁable DNA strands for highly spe-
ciﬁc and sensitive detection of prostate-derived exosomes—prosta-
somes12. Similarly, antibody-DNA conjugates have been used for
ﬂow-cytometric detection of individual exosomes by pairwise liga-
tion of several sets of antibody-DNA conjugates enhanced via
rolling circle ampliﬁcation (RCA) for ﬂuorescence detection20.
However, new technologies are required to survey higher orders of
protein species on large sets of exosomes in parallel in order to
assess their heterogeneity.
Here, we report a proximity-dependent barcoding assay (PBA),
as a high-throughput approach to simultaneously proﬁle 38 sur-
face proteins for their presence on individual exosomes. In PBA,
we use micrometer-sized single-stranded DNA clusters, each
having hundreds of copies of a unique DNA motif, generated via
RCA, to barcode individual exosomes. The protein composition
on the surface of individual exosome is converted to DNA
sequence information via bound antibody-DNA conjugates that
incorporate a random tag sequence repeated in each RCA pro-
duct. After ampliﬁcation by PCR, information about protein and
exosome identity brought together in DNA strands is decoded by
next-generation sequencing to identify the surface protein com-
position of individual exosomes.
Results
Design and workﬂow of PBA. PBA probes were prepared by
conjugating antibodies with DNA oligonucleotides comprising a
8-nucleotide (nt) proteinTag that served to identify the target
exosomal surface protein, and a 8-nt random unique molecular
identiﬁer (UMI) sequence, here referred to as a molecule tag
(moleculeTag), to distinguish individual protein molecules after
PCR ampliﬁcation21 (Fig. 1a). Reagents to barcode individual
exosomes were prepared by RCA of circularized DNA molecules
containing a 15-nt random DNA sequence (complexTag). Each
RCA product includes several hundred identical copies of a
unique complexTag (Fig. 1b), and in the PBA procedure these
become incorporated in the antibody-conjugated oligonucleo-
tides, and serve to identify proteins on individual exosomes
having become colocalized with unique RCA products as
described in Fig. 122.
In PBA, exosomes are mixed with PBA probes in solution
before being captured sparsely in 96-well microtiter wells coated
with cholera toxin subunit B (CTB) that binds GM1 gangliosides
in the exosome membranes23, followed by washes to remove free
antibody conjugates (Supplementary Fig. 1). Diluted RCA
products are then added, allowing individual RCA products,
similar in size to exosomes (Supplementary Fig. 2) to interact
with single exosomes by having their bound PBA probes
hybridize to the RCA products. PBA probes bound to the same
exosome are brought in proximity, and incorporate the same
complexTag from a nearby RCA product by DNA polymerase-
mediated extension (Fig. 1c). Next, the extension products are
ampliﬁed for preparation of a sequencing library. Neither
oligonucleotides on exosomes that have failed to encounter an
RCA product nor isolated RCA products can give rise to
ampliﬁable products. After sequencing ampliﬁcation products,
the reads of each sample are sorted by complexTags and
proteinTags to identify participating proteins on individual
exosomes. By counting the total number of different molecule-
Tags for each of the proteinTags sharing the same complexTag,
all detected protein molecules from individual exosomes in a
sample can be identiﬁed and quantiﬁed.
Validation of PBA using a separate or mixed incubation sys-
tem. To ascertain that PBA could correctly identify members of
protein complexes, we ﬁrst prepared artiﬁcial complexes by
allowing streptavidin (STV) to bind combinations of biotiny-
lated oligonucleotides (Fig. 2a). We incubated STV with oligo-
nucleotides carrying each one of four proteinTags in four
separate preparations, such that each STV in the mixture bound
oligonucleotides with the same proteinTag before these four
STV preparations were combined (separate incubation). If two
different STV-oligonucleotide complexes would be erroneously
identiﬁed by PBA as a single one, then there is an ~75% pos-
sibility that such falsely identiﬁed complexes would involve
more than one proteinTag. For comparison, we also incubated
STV with a mixture of all four biotinylated oligonucleotides,
such that each STV would bind some combination of these four
oligonucleotides (mixed incubation). STV were incubated with
biotinylated oligonucleotides at either a 1:10 or 10:1 molar
ratios. In the analysis of samples from separate preparations, less
than 1% of the recorded complexes included more than one
proteinTag. In the mixed incubation samples with oligonucleo-
tides in excess, 21.0% of the complexes were shown to include
two distinct proteinTags, while 2.4% and 0.2% of complexes had
three or four proteinTags, respectively. As expected, we observed
more complexes with more than one oligonucleotide per STV in
preparations where oligonucleotides were in excess of STV. In
these preparations, the recorded complexes containing 2, 3, or 4
moleculeTags from either separate or mixed preparations were
sorted according to the proteinTags per complex (Fig. 2b). The
majority of the separately prepared complexes contained only 1
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proteinTag, while the majority of complexes prepared with
mixes of the four oligonucleotides contained more than one
proteinTag, with the distribution close to theoretical values. The
results indicate that under the appropriate conditions PBA can
be used to proﬁle individual protein complexes quantitatively,
with minimal risk that proteins from separate complexes are
erroneously clustered together (Supplementary note 1, Supple-
mentary Figs. 3–5). Having established that PBA can identify
members of complexes in the streptavidin model system, we
next investigated the performance of the method for proﬁling
surface proteins on individual exosomes. We prepared four PBA
probes by conjugating CD9 antibodies to two distinct oligonu-
cleotides, forming PBA probes with either proteinTag A (CD9-
TagA) or proteinTag B (CD9-TagB), and conjugating CD63
antibody with two other oligonucleotides to obtain either pro-
teinTag C (CD63-TagC) or proteinTag D (CD63-TagD). We
then mixed antiCD9-TagA and antiCD63-TagC as probe Set1,
and antiCD9-TagB and antiCD63-TagD as the second probe
Set2. Figure 3a presents results from an experiment where
exosomes isolated from the K562 cell line were incubated
separately with the two sets of PBA probes before these were
pooled and subjected to PBA with capture in microwells,
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Fig. 1 Design and workﬂow of PBA. a Preparation of PBA probes by chemical conjugation of antibodies and DNA oligonucleotides containing an 8-nt
proteinTag and an 8-nt random sequence moleculeTag. b Preparation of RCA products from circularized oligonucleotides comprising a 15-nt random
sequence as complexTags, capable of encoding in excess of one billion unique complexTags. c To proﬁle surface proteins of exosomes by PBA, exosomes
are ﬁrst incubated with PBA probes, followed by capture of exosomes with bound PBA probes in microtiter wells via immobilized cholera toxin subunit B
(CTB). Oligonucleotides on PBA probes brought together by binding the same exosome are next allowed to hybridize to a unique RCA product, followed by
enzymatic extension, incorporating the complexTag present in the RCA product along with a standard sequence motif, later used for ampliﬁcation. To
prevent the DNA polymerase from extending across nearby monomers in the RCA products, blocking oligonucleotides are pre-hybridized to the RCA
products. Successfully extended DNA molecules on PBA probes are ampliﬁed by PCR using the PCR primer1 and PCR primer2 for library preparation, while
oligonucleotides on the antibodies or RCA products fail to be ampliﬁed by the PCR primer pairs used for ampliﬁcation. The PCR product were subjected to
DNA sequencing to record the numbers of molecules with speciﬁc tag combinations, thus revealing the identities of proteins on individual exosomes
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annealing to RCA products, extension and sequencing library
preparation. In a parallel reaction (Fig. 3b), the exosomes were
incubated with all four PBA probes, followed by the PBA
workﬂow. In the reaction with separate probe sets we observed
less than 5% of exosomes with PBA probes coming from two
different sets (CD9-TagA with CD9-TagB, CD63-TagC with
CD63-TagD, CD9-TagA with CD63-TagD, or CD9-TagB with
CD63-TagC), while a large majority of the exosomes were tagged
with both CD9 and CD63 from the same probe set (CD9-TagA
and CD63-TagC or CD9-TagB and CD63-TagD; Fig. 3a). By
contrast, in the reaction with mixed probe sets, exosomes were
tagged with probes from both probe sets (Fig. 3b). This again
demonstrated the ability of PBA to analyze individual exosomes
with minimal risk of false identiﬁcation, important for char-
acterizing populations of exosomes in biological samples, as a
basis to evaluate their distinct diagnostic potential.
Proﬁling surface proteins of individual exosomes from differ-
ent sources by PBA. Next, we applied PBA to investigate the
presence of 38 different human proteins on exosomes from
eighteen different human sources—one preparation was isolated
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Fig. 2 Validation of PBA using STV-biotin-oligonucleotide complexes. Tetrameric streptavidin molecules were incubated with four different biotinylated
oligonucleotides, either separately or in a mixture of all four oligonucleotides. Streptavidin and biotinylated oligonucleotides were combined at molar ratios
of 1:10 or 10:1. a The numbers of observed complexes with different numbers of proteinTags and moleculeTags are summarized in pie charts. b When the
oligonucleotides were in excess, the numbers of complexes from separate or mixed oligonucleotides incubation with 2, 3, or 4 moleculeTags were grouped
according to the number of proteinTags per complex. Theoretical ratios were calculated for the mixed sample
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from serum from healthy donors (serum exosomes) and one from
seminal ﬂuid, referred to as prostasomes, which have been sug-
gested to serve as biomarkers for prostate cancer12. Exosomes
were also prepared from conditioned media of the 16 human cell
lines10, BLC21, U87MG, A549, HCT116, PC3, HEK293, COLO1,
K562, KatoIII, MNK45 MNK7, AGS, MM1, DAUD1, BPH-1,
SKNSH, originating from different tissues (see Methods). Each
sample was individually exposed to the PBA probes. The anti-
bodies were chosen to include many known exosomal cancer
markers, previously used to analyze exosomes from cancer cell
lines, with a particular focus on integrin markers, which have
been reported to be relevant for cancer metastasis2.
By counting the total moleculeTags connected with each
protein for each sample, the total protein abundance can be
recorded (Fig. 4a). Some proteins are present in exosomes from
many different samples, e.g., CD151, while some other proteins
e.g., CD227 are only expressed in exosomes from a few sources.
We then investigated if exosomes from different sources have
distinct surface protein patterns. We performed dimensional
reduction of individual exosomes from different sources based on
their surface protein compositions using T-distributed Stochastic
Neighbor Embedding (t-SNE)24 (Fig. 4b). For those exosomes
from any source where only one protein type was observed in our
analysis (n= 172481), no good distinction between sources was
observed. By selecting exosomes where two protein types were
recorded (n= 17345), exosome from different sources were better
resolved, and some protein pairs were preferentially observed on
exosomes from a single sample source. Lastly, we investigated
exosomes for which three or more proteins had been identiﬁed
(n= 61882). Here, exosomes from the same sample sources were
seen to colocalize by t-SNE analysis. For some regions,
exempliﬁed by dotted circles in Fig. 4b, exosomes from particular
sample sources are seen to dominate. This demonstrates that
exosomes from different sources are better distinguished when
more surface proteins are identiﬁed. The PBA analysis does not
necessarily detect all proteins present on a given exosomes
because of less than quantitative antibody binding and limited
sequencing depth.
By comparing the deduced surface protein proﬁles from
individual prostasomes or from exosomes from the K562 cell line
with those found in serum, we identiﬁed combinations of protein
species found mainly in prostasomes (>99%) or in K562
exosomes (>95%) (Fig. 5a). We used this information to mimic
analysis of heterogeneous samples, prepared by spiking in
different amounts of either puriﬁed prostasomes or K562
exosomes or both in a ﬁxed amount of serum exosomes. PBA
analysis revealed the expected correlation between proportions of
added and recorded exosomes with prostasome- or K562-
selective combinations of PBA probes (Fig. 5b–c). Duplicate
measurements demonstrated that the measured proportions were
reproducible (Supplementary Fig. 6). Pairs of antibodies binding
prostasomes as revealed by PBA were also used as probes in solid-
phase proximity ligation assays (SP-PLA) providing efﬁcient
quantitation (Supplementary Fig. 7).
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Discussion
The representation of different classes of exosomes in biological
samples may confer valuable diagnostic information, but this
information is not readily accessible by current methods for
exosome analysis. In biomarker discovery, exosome species that
might be of diagnostic value for disease could be present in low
abundance among other exosome populations in a sample,
obscuring any diagnostic value. Here, we have used DNA
sequencing to decode combinations of antibodies with protein-
speciﬁc DNA tags (proteinTags), binding individual exosomes, by
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associating them via DNA extension with single members of a
large repertoire of DNA bundles—RCA products—with multiple
copies of a particular random DNA tag—the complexTag. We
have used the assays to identify the protein composition of
individual exosomes. PBA can identify and quantify large num-
bers of combinations of proteins from a given set on individual
exosomes or any other clusters of proteins.
PBA is performed in microtiter wells without the need for
compartmentalization in nanowells16 or droplets25–27 or the use
of special equipment, by using large numbers of submicrometer-
sized DNA bundles generated by RCA, similar in size to the
exosomes. Based on the known rate of synthesis by the phi29
DNA polymerase28, RCA products that represent DNA con-
catemers with ~200 complements of a 100-nt DNA circle are
generated after 10 min of replication. Each of these RCA products
thus contains around 200 copies of a unique complexTag that can
be combined with proteinTags to identify proteins present on
individual exosomes. PBA offers a vast capacity for multiplexing
as the current panel of 40 probes, speciﬁc for 38 different pro-
teins, can easily be scaled to larger numbers. We demonstrate that
PBA can be used to distinguish exosomes through their variable
surface protein compositions, enabling analyses of different
populations of exosomes in heterogeneous samples.
The limit of detection by PBA depends on the speciﬁcity of a
given protein combination, the coverage and depth of sequencing,
and the afﬁnity and selectivity of antibodies. To increase the
probability of detecting elevated levels of exosomes from a given
tissue source, targeting tissue-speciﬁc proteins and extending the
protein panel beyond the current 38 proteins may help to further
lower limits of detection. The technique described herein should
also be suitable for mapping other higher-order protein com-
plexes, besides those on the surfaces of exosomes or other
extracellular vesicles.
In summary, we have developed a technique for analyzing
surface proteins of individual exosomes, employing a combina-
tion of antibody-DNA conjugates and unique tag sequences
repeated in large numbers of unique RCA products. By com-
paring the proﬁles of exosomes from different sources, speciﬁc
surface protein combinations can be found and used for identi-
ﬁcation and quantiﬁcation of very large numbers of exosomes
that may be released to blood from speciﬁc tissues in health and
disease.
Methods
Assembly of STV-oligonucleotide complexes. STV was combined with bioti-
nylated oligonucleotides that included proteinTag sequences. Aliquots of recom-
binant STV (ThermoFisher Scientiﬁc) at a concentration of 1 μM were mixed with
an equal volume of PBS containing either each one or a combination of all four
biotinylated oligonucleotides (Supplementary Table 1) at a total concentration of
either 100 nM or 10 μM and incubated at 4 °C overnight. The four separate STV-
oligonucleotides complexes were combined into one, and both this pool and the
preparation with all four oligonucleotides were diluted to a STV concentration of
1 nM in PBS.
Preparation of exosomes from cell culture supernatants or from human body
ﬂuids. Gastric cancer cell lines KATOIII (ATCC® HTB-103), AGS (ATCC® CRL-
1739), MMK7(RIKEN) were cultured at 37 °C under 5% CO2 in RPMI1640
medium with 10% complete fetal bovine serum (FBS), penicillin-streptomycin, and
glutamine. Before exosome isolation, cells were grown in RPMI1640 with 10%
exosome-depleted FBS (EXO-FBS, System Biosciences) for 3–4 days up to 95%
conﬂuency. Cell culture media were collected and protease inhibitor (Complete
Mini, Roche) was added to prevent degradation. Culture media were centrifuged at
3,000 × g for 10 min, and the supernatant was then centrifuged at 10,000 × g for
another 10 min at 4 °C to remove cell debris. The supernatant was passed through a
0.45 µm ﬁlter and then ultracentrifuged at 100,000 × g for 2 h at 4 °C using a
Beckman L8–70M ultracentrifuge. The pellet was resuspended and washed with
cold ﬁltered PBS and ultracentrifuged for 2 h again. The ﬁnal exosome pellet was
resuspended in 50–70 µl of PBS containing protease inhibitor and stored at −80 °C
until use. The concentration of total protein in isolated exosomes was measured
using a Pierce BCA protein assay kit (Thermo Scientiﬁc) and a dot-it-spot-it kit
(Maplestone AB, Sweden). Lyophilized exosomes from BLCL (EBV transformed
lymphoblastoid B cell line, HBM-BLCL-30/2), K562 (pleural effusion, leukemia
chromic myelogenous, HBM-K562–30/2), DAUD1 (human burkitt lymphoma,
HBM-DAUDI-30/2), U87MG (human glioblastoma, HBM-U87–30/2), SKNSH
(human neuroblastoma, HBM-SK-30/2), HEK293 (human embryonic kidney,
HBM-HEK293–30/2), HCT116 (human colon carcinoma, HBM-HCT-30/2),
COLO1(human colon carcinoma, HBM-COLO-30/2), A549 (lung carcinoma,
HBM-A549–30/2), PC3 (human prostate adenocarcinoma grade IV, HBM-
PC3–30/2), BPH-1 (human prostatic hyperplasia), MM1 (human melanoma,
HBM-BPH-30/2), and from serum of healthy donors (HBM-PES-100) were all
purchased from HansaBioMed Life-sciences LLC.
To purify prostasomes, human seminal plasma was centrifuged at 3,000 × g for
10 min, followed by 10,000 × g for 30 min at 4 °C to pellet cell debris. The
supernatant was ultracentrifuged at 100,000 × g for 2 h at 4 °C and the pellet,
containing exosomes, was resuspended in PBS. The resuspended pellet was further
puriﬁed by size-exclusion chromatography on a Superdex 200 gel-ﬁlled XK16/70
column (GE Healthcare), followed by density gradient separation (prostasomes
were recovered in the density range 1.13–1.19 g/ml). The prostasome concentration
was adjusted to 2 mg/ml measured by Pierce BCA protein assay kit and were kept
at −70 °C until use.
Antibodies and oligonucleotides. The antibody preparation directed against
streptavidin was purchased from Thermo Scientiﬁc (S10D4). The sources of
antibodies directed against surface proteins on exosomes are summarized in
Supplementary Table 2. The oligonucleotides used in this study were purchased
from IDT or Solulink (Supplementary Table 1).
Preparation of antibody-oligonucleotide conjugates (PBA probes). The con-
jugation of oligonucleotides to antibodies (Supplementary table 2) was performed
as follows: Twenty μg of each antibody was activated by adding 1 μl of 4 mM Sulfo-
SMCC (Thermo Scientiﬁc) in dimethyl sulfoxide (DMSO; Sigma–Aldrich), and
incubating at room temperature (RT) for 2 h. After 1 h of antibody activation, 3 μl
of each 5’ thiol-modiﬁed oligonucleotide at a concentration of 100 μM was reduced
by adding 12 μl of 100 mM DTT (Sigma–Aldrich) in 1x PBS with 5 mM EDTA,
and incubating at 37 °C for 1 h. The activated antibodies and reduced oligonu-
cleotides were separately puriﬁed using Zeba Spin Desalting Plates, 7 K MWCO
(Thermo Scientiﬁc) according to the manufacturer’s recommended procedure.
Each puriﬁed antibody was then mixed with one type of oligonucleotide (Sup-
plementary Table 1), and directly followed by dialysis in a Slide-A-Lyzer MINI
Dialysis Device, 7 K MWCO, 0.1 ml (Thermo Scientiﬁc) against 5 l PBS with
constant stirring by a magnetic bar at 4 °C overnight. The conjugates were stored at
1 μM antibody concentration in PBS with 0.1% BSA at 4 °C.
Preparation of RCA products. Padlock oligonucleotides, including a 15 nt ran-
dom sequence (100 nM) were ligated into circular DNA strands in the presence of
template (100 nM) in 1x phi29 buffer ((Thermo Scientiﬁc), 10 mM Mg-acetate,
66 mM K-acetate, 0.1% (v/v) Tween 20, 1 mM DTT) containing 0.01 U/μl T4 ligase
(Thermo Scientiﬁc), and 1 mM ATP (Thermo Scientiﬁc). The ligation was per-
formed at 37 °C for 30 min. To remove unligated padlock oligonucleotides, exo-
nuclease I and exonuclease III (Thermo Scientiﬁc) were added to the ligation mix
to a concentration of 0.2 U/μl and 2 U/μl, respectively. The reactions were incu-
bated at 37 °C for 30 min and terminated by incubation at 85 °C for 20 min. Then
the RCA primer (the same oligonucleotide used as ligation template) was adjusted
to a concentration of 100 nM and incubated at 37 °C for 20 min to reanneal to the
circular DNA strands. The RCA reactions were initiated by adding d(A, U, G, C)TP
at concentrations of 1 mM and phi29 polymerase (Thermo Scientiﬁc) at 0.1 U/μl.
RCA was performed at 37 °C for 10 min, and terminated by heating at 65 °C for
10 min. The RCA products were kept at −20 °C until use. The RCA products were
characterized with Nanoparticle Tracking Analysis NTA (Malvern Nanosight
NS300) according to the manufacturer’s instructions.
Capturing STV-biotin oligonucleotide complexes. For each reaction, 200 ng
anti-STV antibodies, diluted in 50 μl 100 mM carbonate buffer (pH 9.6), was added
to 8-well RoboStrip (847–0501000103, Analytik Jena) and incubated overnight at
4 °C. After two washes with 100 μl washing buffer (1x PBS with 0.05% Tween20
(Sigma–Aldrich)), 50 μl blocking buffer (1x PBS with 1% BSA (Sigma–Aldrich))
was added and the plates were incubated at 37 °C for 1 h. After removing the
blocking buffer, pre-assembled STV-oligonucleotides complexes were diluted to
10 pM (according to the concentration of STV) in 20 μl washing buffer, and added
to the antibody-immobilized microplates, and incubated for 1 h at RT.
Probing and capturing exosomes. For each reaction, 50 ng biotinylated CTB
(C-34779, Thermo Scientiﬁc) was diluted in 25 μl PBS and incubated overnight in
STV-coated PCR tubes (PCR0STF-SA5/100, Biomat). The wells in the plates were
then washed twice with 100 μl washing buffer. Exosomes from each sample source
or cell line was mixed with all antibody conjugates (20 nM for each), directed
against surface proteins, in PBA buffer (PBS, 0.05% Tween 20, 5 mM EDTA, 1 mg/
ml salmon sperm DNA (15632011, ThermoFisher Scientiﬁc) and 1% BSA) at 4 °C
overnight. After incubation, 1 μl of the exosome-antibody conjugate complexes
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were diluted in 25 μl PBA buffer, and 20 μl was incubated in wells coated with
biotinylated CTB for 15 min at RT. For replicate measurements, 2 μl of exosomes
were diluted in 50 µl PBA buffer, and 20 μl were added into two separated wells.
Proximity barcoding. The captured STV-oligonucleotide complexes or exosomes
with antibody conjugates were washed twice with 100 μl washing buffer. Then 25 μl
of the RCA products at a concentration of 1 nM and 500 nM blocking oligonu-
cleotide was added to the reaction wells and incubated at 37 °C for 15 min. The
blocking oligonucleotides were used to prevent the DNA polymerase from
extending to adjacent copies of monomers in the RCA products containing the
complexTags. After two washes with 100 μl washing buffer, 25 μl of T4 DNA
polymerase buffer containing 1.25 unit of T4 DNA polymerase and 100 μM d(A, T,
G, C)TP was added and the reaction mix was incubated at RT for 15 min.
Ampliﬁcation of complex-tagged extension products from the antibody-
conjugated oligonucleotides. The reaction mixes were washed and 30 μl of PCR mix
containing 1x Phusion HF Buffer (2mM MgCl2, 0.2mM d(A,T,G,C)TP, 1× SYBR
Green I, 1% DMSO, 500 nM PCR primers (pba-fwd and pba-rev), 0.02 U/μl Phusion
polymerase and 0.02 U/μl Uracil-DNA glycosylase (all from Thermo Scientiﬁc) was
added to each reaction well. The plate was then transferred to a thermal cycler
(MX3005; Stratagene) for qPCR with an initial incubation of 37 °C for 15min, then
95 °C for 2min, followed by 30 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s.
Sample indexing and library preparation for sequencing. After PCR ampliﬁ-
cation of extension products from PBA reactions, 1 μl of the ampliﬁcation reaction
was spiked in 10 μl of index PCR mix containing 10 μM each of fwd-index and rev-
index primer pairs, and the reactions were incubated for an initial 2 min at 95 °C,
followed by two cycles of 95 °C for 15 s, 60 °C for 60 s, and 72 °C for 60 s. The
indexed PCR products were diluted 20 times into new PCR mixes containing 1x
Phusion HF Buffer (Thermo Scientiﬁc), 0.2 mM d(A, T, G, C)TP (Thermo Sci-
entiﬁc), 1× SYBR Green I (Thermo Scientiﬁc), 1% DMSO, 500 nM PCR primers
(library-fwd and library-rev) and programmed for an initial 2 min at 95 °C, and 15
cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s. The PCR products were
pooled and puriﬁed using QIAquick PCR Puriﬁcation Kit. The puriﬁed DNA was
sequenced using MiSeq Reagent Kit v2, 300 cycles by MiSeq or NextSeq Reagent
Kit 75SE, NextSeq (Illumina).
SP-PLA for prostasome detection in 10% human plasma. Biotinylated CD26
and CD59 were prepared using ChromaLink Biotin Labeling Reagent (Solulink B-
1007–105) with 20-fold molar excess of biotin reagent over antibody according to
the manufacturer’s protocol. Before biotinylation, antibodies were puriﬁed using
Zeba Spin Desalting Column, 7 K MWCO (Thermo Scientiﬁc, 89882) according to
the manufacturer’s recommended procedure and in PBS at concentration of 2 mg/
ml. After biotinylation, the antibodies were puriﬁed again with Zeba Spin Desalting
Column to remove excess biotin reagents. Dynabeads MyOne Streptavidin T1
(100 μl, 1 mg, ThermoFisher Scientiﬁc, 65601) was washed twice with 500 μl
washing buffer (PBS with 0.05% Tween 20), and 200 μl of 50 nM CTB-biotin
conjugates (C34779) were added to the beads and the suspensions were incubated
for 1 h at RT on a rotator. The beads were then washed twice with 500 μl PBST and
reconstituted in 200 μl PBS containing 0.1% BSA. PLA probes (CD26-SLC1 and
CD59-SLC2) were prepared by mixing 100 nM of biotinylated CD26 and CD59
with 100 nM streptavidin-conjugated oligonucleotides (SLC1 and SLC2, Solulink)
at same volume separately and incubated for 30 min at RT. Then two probes were
diluted in PLA buffer (1 mM D-biotin, 0.1% puriﬁed BSA, 0.05% Tween 20,
100 nM goat IgG, 0.1 μg/μl salmon sperm DNA, 5 mM EDTA in PBS) to 1 nM,
incubated for 30 min at RT and mixed at same volume. The ﬁnal concentration for
each probe is 500 pM.
Puriﬁed prostasomes were serially diluted in 10% human plasma (in PLA
buffer). Each dilution series included a negative control with only 10% human
plasma in PLA buffer. Diluted prostasomes (45 μl) were mixed with a suspension of
CTB-coated beads (5 μl) and the reactions were incubated for 1.5 h at RT on an
end-to-end rotator. The beads were then washed twice in 100 μl PBST using a 96-
well magnetic rack. Fifty μl of 500 pM pairs of PLA probes were added into each
reaction well, incubated for 1.5 h at RT, and the beads were washed twice in 100 μl
PBST. A 50 μl ligation and PCR mixture (1 × PCR buffer, 2.5 mM MgCl2, 0.5 ×
Sybr Green I, 0.1 μM BioFwd primer, 0.1 μM BioRev primer, 0.1 μM BioSplint,
0.08 mM ATP, 0.2 mM dNTP (with dUTP), 0.03 U/μl AccuStart Taq DNA
polymerase, 0.01 U/μl T4 ligase and 0.002 U/μl Uracil-DNA glycosylase) was added
to each well. Real-time PCR was performed in MX3005 cycler (Life technologies,
CA, USA) programmed at 95 °C for 2 min, followed by 40 cycles of 95 °C for 15 s
and 60 °C for 1 min.
Data analysis. The BCL ﬁles for each sample were converted to fastq formats by
using bcl2fastq (Illumina) with pair indexes. Then the complexTag, proteinTag,
and moleculeTag were extracted from three ﬁxed segments within each read. Reads
with only one count were removed from the analysis. The tags were then
sequentially sorted according to complexTag, proteinTag, and moleculeTag using
an in-house developed Perl script. The number of exosomes with given combi-
nations of proteins were calculated using an in-house developed R script. The t-
SNE algorithm applied was implemented in the R package Rtsne, and all the
parameters were set to default in our pipeline.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting this study are available in Figshare. FASTQ ﬁles used in this study
are available by https://doi.org/10.6084/m9.ﬁgshare.7956023. The protein abundance on
individual exosomes of each sample are available by https://doi.org/10.6084/m9.
ﬁgshare.7963742.
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